COVID-19 Diagnostic Testing Market: Insights, Competition and 2020-2025 Forecast

June 4, 2020

COVID-19 Diagnostic Testing Global Market is estimated to be valued at USD 44,481.8 million for the year 2020 owing to a rapid increase in the number of coronavirus cases across the globe which boosts the demand for COVID-19 diagnostic tests.

The COVID-19 diagnostic tests are critical in the management of the current pandemic for accurate diagnosis as well as to tackle the spread of the infection. Also, Global COVID-19 Diagnostic Testing market in terms of COVID-19 Tests is expected to reach the number of 329.17 million in the year 2020.

In March 2020, the Food and Drug Administration (FDA) gave Emergency Use Authorization (EUA) to the first POC test-Xpert Xpress test made by Cepheid-for COVID-19 analysis. Abbott and Chembio Diagnostics are among the dynamic market players working for the purpose of care commercial center. The WHO has encouraged healthcare organizations to focus on COVID-19 indicative testing in light of this emergency.

The companies are also adopting profitable strategic moves to gain a competitive edge in the market. For example, in May 2020, Quest Diagnostics announced its collaboration with Ortho Clinical Diagnostics aimed at the expansion of COVID-19 antibody testing across more than 20 laboratories of Quest throughout U.S. The company applied VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Test of Ortho to ramp up the coronavirus testing in patients.

Among the Test Type segment in the COVID-19 Diagnostic Testing market (Molecular Tests, Serology Tests), Molecular Test type segment has been gaining popularity among other segments. Robust funding and speculations by public as well as private organizations are relied upon to impel molecular diagnostic organizations to create COVID-19 symptomatic products, in this way driving the market.

Based on End-User segment, Private or Commercial labs segment holds the major share in the COVID-19 diagnostic testing market followed by Public health labs and hospitals. Due to the growing number of COVID-19 cases across the globe, it has become imperative for the government of the various countries to involve a greater number of private or commercial firms in providing diagnostic testing in order to enhance the testing capacity to detect the virus.

Scope of the Report

  • The report analyses the COVID-19 Diagnostic Testing market by Value and by COVID-19 Tests.
  • The report analyses the COVID-19 Diagnostic Testing Market by Test Type (Molecular Tests, Serology Tests).
  • The report assesses the COVID-19 Diagnostic Testing market by End-User (Public Health Labs, Private or Commercial Labs, Others).
  • The Global COVID-19 Diagnostic Testing Market has been analysed by Region (Americas, Europe, Asia Pacific) and by Country (United States, Canada, Brazil, Germany, France, Italy, United Kingdom, Spain, Russia, China, Japan, India, South Korea, Singapore)
  • The major trends, drivers and challenges of the industry has been analysed in the report.
  • The report tracks competitive developments, COVID-19 vaccine development. The companies analysed in the report include Biomerieux, Roche Holding AG, Siemens Healthineers, Abbott Laboratories, Becton Dickinson, Thermo Fisher Scientific, Cepheid, BGI Genomics, Seegene, PerkinElmer.
  • The report presents the analysis of COVID-19 Diagnostic Testing market for the forecast period of 2020-2025.

Key Topics Covered

1. Report Scope and Methodology

1.1 Scope of the Report

1.2 Research Methodology

1.3 Executive Summary

2. Strategic Recommendations

3. Global COVID-19 Diagnostic Testing Market: Product Outlook

4. Global COVID-19 Diagnostic Testing Market: Sizing and Forecast

4.1 Market Size, by Value, Year 2020-2025

4.2 Market Size, by COVID-19 Tests, Year 2020-2025

5. Global COVID-19 Diagnostic Testing Market Segmentation by Test Type

5.1 Competitive Scenario of Global COVID-19 Diagnostic Testing: by Test Type

5.2 Molecular Tests-Market Size and Forecast (2020-2025)

5.3 Serology Tests-Market Size and Forecast (2020-2025)

6. Global COVID-19 Diagnostic Testing Market Segmentation by End-User

6.1 Competitive Scenario of Global COVID-19 Diagnostic Testing: by End-User

6.2 Public Health Labs-Market Size and Forecast (2020-2025)

6.3 Private or Commercial Labs-Market Size and Forecast (2020-2025)

6.4 Others-Market Size and Forecast (2020-2025)

7. Global COVID-19 Diagnostic Testing Market: Regional Analysis

7.1 Competitive Scenario of Global COVID-19 Diagnostic Testing: by Region, by Value

8. Americas COVID-19 Diagnostic Testing Market: Segmentation by Test Type, End-User (2020-2025)

9. Europe COVID-19 Diagnostic Testing Market: Segmentation by Test Type, End-User (2020-2025)

10. Asia Pacific COVID-19 Diagnostic Testing Market: Segmentation by Test Type, End-User (2020-2025)

11. Global COVID-19 Diagnostic Testing Market Dynamics

11.1 Global COVID-19 Diagnostic Testing Market Drivers

11.2 Global COVID-19 Diagnostic Testing Market Restraints

11.3 Global COVID-19 Diagnostic Testing Market Trends

12. COVID-19 Vaccine Development

12.1 Overview of Vaccine Development

12.2 Overview of the leading vaccine candidates

13. Competitive Landscape

14. Company Profiles (Business Description, Financial Analysis, Business Strategy)

14.1 bioMerieux

14.2 Roche Holding AG

14.3 Siemens Healthineers

14.4 Abbott Laboratories

14.5 Becton Dickinson

14.6 Thermo Fisher Scientific

14.7 Cepheid

14.8 BGI Genomics

14.9 Seegene

14.10 PerkinElmer

For more information visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”